Gislason et al. concluded that selective COX-2 inhibition with rofecoxib and celecoxib increased the mortality at all doses in patients with prior myocardial infarction; however, the underlying mechanisms were not studied [27]. Here, PTGS2 is linked to myocardial infarction.